{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red37\green37\blue37;
\red33\green33\blue33;
\red119\green119\blue119;
\red107\green107\blue106;
\red14\green86\blue140;
\red255\green255\blue102;
\red80\green80\blue80;
\red21\green137\blue21;
\red204\green204\blue204;
\red246\green246\blue246;
\red247\green247\blue247;
\red238\green238\blue238;
\red20\green93\blue164;
\red51\green51\blue51;
\red56\green124\blue43;
\red151\green151\blue151;
\red181\green79\blue104;
\red0\green114\blue54;
\red106\green144\blue39;
\red239\green122\blue2;
\red187\green187\blue187;
\red182\green231\blue243;
\red112\green112\blue112;
\red254\green254\blue0;
\red232\green233\blue232;
\red249\green249\blue249;
\red255\green248\blue96;
\red240\green240\blue240;
\red105\green105\blue105;
\red227\green227\blue227;
\red255\green210\blue183;
\red233\green233\blue233;
\red249\green250\blue251;
\red228\green231\blue232;
\red245\green245\blue245;
\red102\green0\blue102;
\red203\green203\blue203;
\red61\green61\blue61;
\red255\green255\blue174;
\red242\green242\blue242;
\red118\green118\blue118;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red236\green236\blue236;
\red127\green127\blue127;
\red183\green242\blue206;
\red204\green255\blue255;
\red24\green140\blue181;
\red255\green194\blue211;
\red190\green190\blue252;
\red248\green161\blue28;
\red111\green34\blue109;
\red120\green162\blue47;
\red251\green252\blue255;
\red72\green72\blue72;
\red190\green195\blue204;
\red208\green208\blue208;
\red71\green120\blue194;
\red229\green243\blue255;
\red179\green218\blue255;
\red172\green172\blue172;
\red9\green56\blue84;
\red214\green214\blue214;
\red255\green255\blue204;
\red255\green204\blue0;
\red214\green9\blue9;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 serif;}{
\f6 Source Sans Pro;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj \paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Athena Diagonistics, Inc. v. Mayo Collaborative Services, LLC, Not Reported in Fed....
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_33}{\*\bkmkend co_document_33}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I128115106ca211e69e6ceb9009bbadab_Target}{\*\bkmkend I128115106ca211e69e6ceb9009bbadab_Target}
\par 
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb100 
2016 WL 4491832
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Only the Westlaw citation is currently available.
\par 
}
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, D. Massachusetts.
\par 
}
}
}
{\b0 \qc \cf19 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf19 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf19 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
ATHENA DIAGONISTICS, INC., 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5001036002)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Isis Innovation Limited
}}}
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
, and Max-Planck-Gesellschaft zur Forderung Der Wissenschaften E. V., Plaintiffs,
\par 
}
}
{\b0 \qc \cf19 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf19 \f3 \ri120 \i0 \fs24 \li120 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5044064569)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
MAYO COLLABORATIVE SERVICES, LLC
}}}
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
, d/b/a Mayo Medical Laboratories, and Mayo Clinic, Defendants.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Civil Action No: 15-cv-40075-IT
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Signed 08/25/2016
\par 
}
}
}
}
{\b1 \cf20 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_33}{\*\bkmkend co_attorneysAndLawFirms_33}
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0446390101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Manleen K. Singh
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Robins, Kaplan, Miller & Ciresi LLP, Boston, MA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0471160201&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Andrew J. Kabat
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0129224401&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Emmett J. McMahon
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Robins Kaplan LLP, Minneapolis, MN, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0366977301&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Matthew Bowen McFarlane
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Robins Kaplan LLP, New York, NY, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0448262401&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Tara S.G. Sharp
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Robins Kaplan LLP, Atlanta, GA, for Plaintiffs.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0378873201&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Adam J. Kessel
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Fish & Richardson, P.C., Boston, MA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0412974901&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Elizabeth M. Flanagan
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0487049701&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kelly Allenspach Del Dotto
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Fish & Richardson P.C., Wilmington, DE, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0328155601&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
John C. Adkisson
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0182566101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jonathan E. Singer
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Fish & Richardson PC, Minneapolis, MN, for Defendants.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf20 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_33}{\*\bkmkend co_opinion_33}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib24992d2fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib24992d2fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib29800f1fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib29800f1fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib29800f1fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib29800f1fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb800 
MEMORANDUM & ORDER
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0483993201&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
TALWANI
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, D.J.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_1_33}{\*\bkmkend co_pp_sp_999_1_33}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Plaintiffs Athena Diagnostics, Inc., Isis Innovation Limited, and Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., allege that two tests developed by Defendants Mayo Collaborative Services, LLC, and Mayo Clinic, infringe on Plaintiffs\rquote  patent, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820 (\u8220\'3f\rquote 820 Patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Third Am. Compl. (\u8220\'3fComplaint\u8221\'3f) [#92]. Defendants move to dismiss Plaintiffs\rquote  complaint arguing that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because the claimed method applies routine and conventional techniques to a law of nature. Defs.\rquote  Rule 12(b)(6) Mot. Dismiss (\u8220\'3fDefs.\rquote  Mot. Dismiss\u8221\'3f) [#25]. The motion is DENIED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib298eb51fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib298eb51fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib298eb51fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib298eb51fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
Facts
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 Patent
}}}
\sa200 
\sb400 
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 allows for the diagnosis of a form of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a chronic 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic39e7bac475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
autoimmune disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 l. 13. Patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 experience waning muscle strength throughout the day, and symptoms include eye weakness (
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic14c9c9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
drooping eyelids
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, double vision), leg weakness, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic981bf50475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
dysphagia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (difficulty swallowing) and slurred or nasal speech. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 l. 15-23. In 1960, it was discovered that in 80% of patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, antibodies attack the acetyle 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd99602475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
choline
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 receptor (AChR) (a neurotransmitter). In those patients, diagnosis is achieved through tests which detect the presence of AChR autoantibodies. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 l. 34-36. Autoantibodies \u8220\'3fare naturally occurring antibodies directed to an antigen which an individual\rquote s immune response recognizes as foreign even though that antigen actually originated in the individual.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 l. 42-45. However, 20% of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patients do not have the AChR autoantibodies despite experiencing the same symptoms and responding to the same therapies. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 l. 36-40. For the 20% of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patients who do not have the AChR autoantibodies, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inventors discovered that they had IgG antibodies that attack the N-terminal domains of muscle specific tyrosine kinase (\u8220\'3fMuSK\u8221\'3f), a receptor that is located on the surface of neuromuscular junctions. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 l. 55-61.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patent describes the method for a more accurate and speedy diagnosis of these patients. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 3 l. 4-7. Specifically, the patent describes a method for diagnosing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in which a radioactive label is attached to MuSK (or a fragment thereof) and is then introduced to a sample of bodily fluid. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 3-4 l. 65-10. The method specifies that 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I be used as the radioactive label. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 4 l. 10. When 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK is introduced into the sample of bodily fluid, the MuSK autoantibodies, if present, attach to the labeled fragment. After the bodily fluid is immunoprecipitated, the presence of the radioactive label on any antibody indicates that the person is suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 4 l. 8-10.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib29c94d0fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib29c94d0fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
B. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
Infringement Allegations
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_2_33}{\*\bkmkend co_pp_sp_999_2_33}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*2
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Athena\rquote s test, FMUSK, uses the patented method to diagnose neurotransmission or developmental disorders related to MuSK. Compl. [#92 \u182\'3f 16]; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Claim 1. Plaintiffs allege that \u8220\'3fDefendants, with specific knowledge of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the method it covers, surreptitiously and purposefully designed an alternate test to avoid paying Athena for Athena\rquote s licensed FMUSK test.\u8221\'3f Compl. [#92 \u182\'3f 20]. Plaintiffs allege that Defendants availed themselves of the technology disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and developed two tests for diagnosing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patients. Compl. [#92 \u182\'3f 18]. Plaintiffs argue that Defendants\rquote  actions directly or indirectly, and literally or under the doctrine of equivalents, infringe the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Compl. [#92 \u182\'3f 24]. The claims at issue are those listed in claims 6-9 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Pls.\rquote  Mem. Opp\rquote n Defs.\rquote  Mot. Dismiss. 24 [#37]. Plaintiffs concede that they will not pursue infringement claims against Defendants based on the other claims in the patent. Pls.\rquote  Mem. Opp\rquote n Defs.\rquote  Mot. Dismiss 8 [#37].
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib29e90a1fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib29e90a1fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib29e90a1fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib29e90a1fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
II. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
Motion to Dismiss
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Defendants move to dismiss the complaint on the ground that the patent seeks to patent a law of nature, and it uses techniques standard in the art. Defs.\rquote  Mem. Supp. Mot. Dismiss 5 [#26]. Plaintiffs argue that the patent is not directed at a law of nature because the patent requires the production and use of 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK, a non-naturally occurring protein. Plaintiffs also argue that applying various known types of procedures to a non-naturally occurring protein transforms the claim and makes it patent eligible. Pls.\rquote  Mem. Opp\rquote n Defs.\rquote  Mot. Dismiss 14 [#37].
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib29fc921fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib29fc921fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
Standard of Review under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
\sa200 
\sb400 
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In applying 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at the pleading stage, the court construes the patent claims in a manner most favorable to the non-moving party. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035137097&pubNum=0000506&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1349&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1349" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Content Extraction & Transmission LLC v. Wells Fargo Bank, Nat\rquote l Ass\rquote n
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 776 F.3d 1343, 1349 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
cert. denied
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036484462&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
136 S. Ct. 119 (2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As a threshold requirement for patent protection, the subject matter of a patent must be patentable under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; otherwise, the patent is invalid. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 states \u8220\'3f[w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Supreme Court has held that this section contains an implicit exception: \u8220\'3f[l]aws of nature, natural phenomena, and abstract ideas are not patentable.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd. v. CLS Bank Intern.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, ___ U.S. ____, 134 S. Ct. 2347, 2354 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2116&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2116" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Association for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, ___ U.S. ____, 133 S. Ct. 2107, 2116 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Although \u8220\'3fall inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas,\u8221\'3f these three patent-ineligible exceptions prevent \u8220\'3fmonopolization\u8221\'3f of the \u8220\'3fbasic tools of scientific and technological work\u8221\'3f and the impeding of innovation. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1293&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1293" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, ___ U.S. ____, 132 S. Ct. 1289, 1293 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To distinguish between patents that claim laws of nature, natural phenomena, and abstract ideas from patent-eligible inventions, the court must first determine whether the claims at issue are directed to one of those patent-ineligible concepts. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If the concept is patent ineligible, the court then considers the elements of each claim both \u8220\'3findividually and \u8216\'3fas an ordered combination\u8217\'3f to determine whether the additional elements \u8220\'3ftransform the nature of the claim\u8221\'3f into a patent-eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1298&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1298" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S. Ct. at 1298, 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). \u8220\'3fWe have described step two of this analysis as a search for an \u8216\'3finventive concept\u8217\'3f \u8211\'3f i.e., an element or combination of elements that is \u8216\'3fsufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S. Ct. at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). At step two, more is required than well-understood, routine, conventional activity already engaged in by the scientific community. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000999&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Rapid Litigation Management, Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, ___ F.3d ____, 2016 WL 3606624, *3 (Fed. Cir. July 5, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib2a54761fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib2a54761fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
B. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb400 
Step One: Are Claims Directed to a Patent Ineligible Concept?
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_3_33}{\*\bkmkend co_pp_sp_999_3_33}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*3
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Defendants argue that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed at a law of nature: that the bodily fluid of some people with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 have autoantibodies to MuSK. Plaintiffs argue that the patent method uses a man-made, patent eligible molecule, and uses that chemical complex in an innovative and transformative manner. Pls.\rquote  Surreply Opp\rquote n Mot. Dismiss 4 [#46]. Per Plaintiffs, the claims are not directed to MuSK, instead, the claims \u8220\'3f[r]ecite using a man-made chemically-modified version of MuSK to form a specific complex that does not occur in nature\u8221\'3f and are therefore patent eligible. Pls.\rquote  Surreply Opp\rquote n Mot. Dismiss 5 [#46].
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patent describes a method in which 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK is put into a sample of bodily fluid, and then the bodily fluid is filtered so that autoantibodies attached to the 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK are detected. The presence of the 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK autoantibodies indicates the person suffers from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The relevant portion of the patent states:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The invention claimed is:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 A method for diagnosing neurotransmission or developmental disorders related to muscle specific tyrosine kinase (MuSK) in a mammal comprising the step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of muscle specific tyrosine kinase (MuSK).
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 A method according to claim 1 wherein said method comprises the steps of:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
a) contacting said bodily fluid with muscle specific tyrosine kinase (MuSK) or an antigenic determinant thereof: and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
b) detecting any antibody-antigen complexes formed between said receptor tyrosine kinase or an antigenic fragment thereof and antibodies present in said bodily fluid, wherein the presence of said complexes is indicative of said mammal suffering from said neurotransmission or development disorders.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
3.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 A method according to Claim 2 wherein said antibody-antigen complex is detected using an anti-IgG antibody tagged or labeled with a reporter molecule.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
...
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
6.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 A method according to claim 3 whereby the intensity of the signal from the anti-human IgG antibody is indicative of the relative amount of the anti-MuSK autoantibody in the bodily fluid when compared to a positive and negative control reading.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
7.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 A method according to claim 1, comprising contacting MuSK or an epitope or antigenic determinant thereof having a suitable label thereon, with said bodily fluid, immunoprecipitating any antibody/MuSK complex or antibody/MuSK epitope or antigenic determinant complex from said bodily fluid and monitoring for said label on any of said antibody/MuSK complex or antibody/MuSK epitope or antigen determinant complex, wherein the presence of said label is indicative of said mammal is suffering from said neurotransmission or developmental disorder related to muscle specific tyrosine kinase (MuSK).
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
8.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 A method according to claim 7 wherein said label is a radioactive label.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
9.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 A method according to claim 8 wherein said label is 125I.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Plaintiffs argue that because 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK is not naturally occurring, the claim is patent eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Pls.\rquote  Mem. Opp\rquote n Defs.\rquote  Mot. Dismiss. 11 [#37] (\u8220\'3fThose antibody/MuSK complexes are created in the laboratory and result from the use of a non-naturally-occurring laboratory-created molecule, 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK, and therefore, the antibody/MuSK complexes formed and detected by claim 9 are not found in nature.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
While 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK and the antibody/MuSK complexes are not found in nature, this does not transform the patent at issue here to a patent eligible concept. Contrary to Plaintiffs\rquote  argument, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is not a composition patent directed at the creation of the 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK auto-antibody complex. Rather, the patent is directed at a method for the diagnosis of a disease. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 1 l. 9-11 (\u8220\'3fThe present invention is concerned with neurotransmission disorders and, in particular, with a method of diagnosing such disorders in mammals.\u8221\'3f). Although the patented method uses man-made 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK, the use of a man-made complex does not transform the subject matter of the patent. The focus of the claims of the invention is the interaction of the 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK and the bodily fluid, an interaction which is naturally occurring. The purpose of the patent is to detect whether any antibody-antigen complexes are formed between the 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK receptor and the antibodies \u8220\'3fpresent in said bodily fluid.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Claim 2. Counter to Plaintiffs\rquote  argument, because the patent focuses on this natural occurrence, it is directed to a patent-ineligible concept. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039474697&pubNum=0000999&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Electric Power Group, LLC v. Alstom S.A.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, ___ F.3d. ____, 2016 WL 4073318, at *3 (Fed. Cir. Aug. 1, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[W]e have described the first-stage inquiry as looking at the \u8216\'3ffocus\u8217\'3f of the claims, their \u8216\'3fcharacter as a whole.\u8217\'3f \u8221\'3f) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1335" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Enfish, LLC v. Microsoft Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 822 F.3d 1327, 1335-36 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_4_33}{\*\bkmkend co_pp_sp_999_4_33}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*4
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Athena\rquote s patent is similar to the patent invalidated by the Supreme Court in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court invalidated the patent of a diagnostic test which measured how well a person metabolized thiopurine drugs. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1295&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1295" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
132 S. Ct. at 1295
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The patent claimed a method in which the drug 6-thioguanine was given to a person, after which the level of 6-thioguanine in the person\rquote s blood stream was measured. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court held that the patent method was directed to observing a law of nature. \u8220\'3fPrometheus\rquote  patents set forth laws of nature-namely, relationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of thiopurine drug will prove ineffective or cause harm.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1296&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1296" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1296
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While the Court acknowledged that it took human action (the administration of a thiopurine drug) to trigger the desired reaction, the reaction itself happened apart from any human action. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court found the claim invalid because the method sought to measure how well a person metabolizes the drug. The Court described the interactions as \u8220\'3fentirely natural processes.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Likewise, Plaintiffs\rquote  method seeks to measure autoantibodies that have attached to a receptor protein, an interaction which is a similarly natural process. In 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a man-made substance was administered to a person, and the by-product of the metabolization of that man-made substance was observed. Here, a man-made substance (
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK) is administered to a sample of bodily fluid, and the by-product (
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-MuSK autoantibodies) is observed. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S. Ct. at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Genetic Tech. Ltd. v. Merial LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d 1369, 1376 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (finding that when the patent claim focuses on a newly discovered fact about human biology, the claim is directed to unpatentable subject matter).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Further support can be found in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Ariosa Diagnostics, Inc. v. Sequenom, Inc.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d 1372 (Fed. Cir. 2015), 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
cert
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
denied
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&pubNum=0000708&cite=136SCT2511&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
136 S. Ct. 2511 (2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The case involved the patent for a method using fetal DNA for the diagnosis of certain conditions. The inventors discovered that cell-free fetal DNA (\u8220\'3fcffDNA\u8221\'3f) was present in maternal plasma and serum. By implementing a method for detecting the small fraction of paternal cffDNA in the maternal plasma or serum, the inventors were able to determine certain inherited characteristics. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1373&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1373" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1373
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The patent method isolated and amplified cffDNA, allowing for greater efficiency in diagnosis of genetic defects. As the court noted, \u8220\'3f[t]he only subject matter new and useful as of the date of the application was the discovery of the presence of cffDNA in maternal plasma or serum ...\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1377
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Likewise, what is new and useful here is the discovery that some patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 have MuSK autoantibodies in their bodily fluid.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Relying on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000999&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Rapid Litigation Mgmt. Ltd.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2016 WL 3606624 at *4
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Plaintiffs seek to distinguish the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 from 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by arguing that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 820 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is focused on the steps required by the claimed method, rather than on the outcome of the diagnostic test. In 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Rapid Litigation Mgmt. Ltd.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, patent inventors discovered that hepatocytes, special liver cells that are used for testing, diagnostic, and treatment purposes, could be refrozen. Refreezing of hepatocytes was a breakthrough because the cells naturally have a short life span, and can only be harvested from a limited number of people. Prior to the discovery, hepatocytes could only be frozen one time, which limited their utility. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *1. The patented method importantly allowed for multi-donor hepatocyte pools, a useful research tool that allows the study of a drug\rquote s impact on a representative population. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Federal Circuit found the \u8220\'3fend result of the \lquote 929 patent claims is not simply an observation or detection of the ability of hepatocytes to survive multiple freeze thaw cycles. Rather, the claims are directed to a new and useful method of preserving hepatocyte cells.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at * 4. The court found that the process\rquote  \u8220\'3fdesired outcome\u8221\'3f was a method to produce something useful, and therefore was not directed at a patent ineligible concept. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The method allowed for refrozen hepatocyte cells to be used in a myriad of ways. Conversely, the desired outcome of the Plaintiffs\rquote  method is the detection of MuSK autoantibodies. It does not produce something useful beyond that diagnosis.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiffs\rquote  argument that the patent is transformed by the use of a man-made molecule is unavailing. The stated purpose of the patent is to diagnose 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myasthenia Gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and the method is directed to a patent ineligible law of nature under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib2b76fd1fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib2b76fd1fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
C. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Step Two: Does the Inventiveness of the Claim make it Patent Eligible
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
?
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_5_33}{\*\bkmkend co_pp_sp_999_5_33}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*5
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 While the patent is directed to a patent ineligible concept under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the patent can still be upheld if the method contains an \u8220\'3finventive concept.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Defendants argue that Plaintiffs\rquote  patent fails step two of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis because it uses well-known techniques for identifying the presence of autoantibodies to MuSK and therefore does not contain an \u8220\'3finventive concept.\u8221\'3f 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Defs.\rquote  Mem. Supp. Mot. Dismiss 14 [#26] (\u8220\'3f[P]rocess steps that recite techniques scientists would have already known to use in conjunction with the newfound natural law cannot supply the inventive concept.\u8221\'3f). Defendants cite to the patent specification which states that \u8220\'3f[i]ondination and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iac925e4a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunoprecipitation
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are standard techniques in the art, the details of which can be found in references (4 and 6).\u8221\'3f Defs.\rquote  Mem. Supp. Mot. Dismiss 10 [#26]; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2013154718&pubNum=0004074&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=PA&docFamilyGuid=Ie1a02359605411dca1e6fa81e64372bf&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,267,820
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 4, l. 9-12. Defendants note that the two publications referenced in the specification date from 1976 and 1985, and according to Defendants the publications describe \u8220\'3f(1) the introduction of a 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I-labeled antigen (AChR) into a bodily fluid sample, (2) 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iac925e4a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunoprecipitation
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and (3) detecting the radioactive label.\u8221\'3f Defs.\rquote  Mem. Supp. Mot. Dismiss 10 [#26]. Defendants argue that the publications show that the methods described in the patent are commonly used by researchers in the field, and thus the claims do not pass step two of the analysis under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Plaintiffs argue that a Rule 12(b)(6) motion cannot rely on extrinsic evidence to support the claim for dismissal, and that novelty and obviousness questions involve factual determinations that cannot be determined at the pleading stage. Pls.\rquote  Mem. Opp\rquote n Mot. Dismiss 22 [#37].
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The court cannot determine at this junction whether Plaintiffs\rquote  patented method uses standard techniques in the art, or whether it is sufficiently inventive to be patentable under the second step of 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While it may later be established that the Plaintiffs\rquote  process is not deserving of patent protection because the techniques are standard in the art and therefore fail to provide an inventive concept, the court cannot resolve these factual determinations at the motion to dismiss stage. On the face of the claims and specification of the patent-in-suit, as well as on the face of the complaint, the court cannot determine as a matter of law whether the patent provides a \u8220\'3fcombination of steps\u8221\'3f to transform the method into a patent-eligible invention. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_708_2360&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2360" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. at 2360
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; see 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038097669&pubNum=0000506&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_506_1325&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1325" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mortgage Grader, Inc. v. First Choice Loan Services, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 811 F.3d 1314, 1325 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fWhether a claim is directed to statutory subject matter is a question of law. [D]etermination of this question may require findings of underlying facts specific to the particular subject matter and its mode of claiming[.]\u8221\'3f) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1992055261&pubNum=0000350&originatingDoc=I128115106ca211e69e6ceb9009bbadab&refType=RP&fi=co_pp_sp_350_1055&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1055" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Arrythmia Research Tech., Inc. v. Corazonix Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 958 F.2d 1053, 1055-56 (Fed. Cir. 1992)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib2bc2ac1fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib2bc2ac1fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib2bc2ac1fd4f11e8881d9d476c1b9}{\*\bkmkend co_anchor_Ib2bc2ac1fd4f11e8881d9d476c1b9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
III. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
Conclusion
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the foregoing reasons, Defendants\rquote  
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Motion to Dismiss
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 [#25] is DENIED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf20 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_33}{\*\bkmkend co_allCitations_33}
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Not Reported in Fed. Supp., 2016 WL 4491832
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf21 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf21 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf21 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf21 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf21 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf21 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf21 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }